196 related articles for article (PubMed ID: 36920813)
1. Osteoporosis: Common Questions and Answers.
Harris K; Zagar CA; Lawrence KV
Am Fam Physician; 2023 Mar; 107(3):238-246. PubMed ID: 36920813
[TBL] [Abstract][Full Text] [Related]
2. The clinician's guide to prevention and treatment of osteoporosis.
LeBoff MS; Greenspan SL; Insogna KL; Lewiecki EM; Saag KG; Singer AJ; Siris ES
Osteoporos Int; 2022 Oct; 33(10):2049-2102. PubMed ID: 35478046
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Osteoporosis.
Jeremiah MP; Unwin BK; Greenawald MH; Casiano VE
Am Fam Physician; 2015 Aug; 92(4):261-8. PubMed ID: 26280231
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of osteoporosis.
Palacios S
Climacteric; 2022 Feb; 25(1):43-49. PubMed ID: 34382489
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
6. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
[TBL] [Abstract][Full Text] [Related]
8. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
[TBL] [Abstract][Full Text] [Related]
9. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.
; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Pignone M; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2018 Jun; 319(24):2521-2531. PubMed ID: 29946735
[TBL] [Abstract][Full Text] [Related]
10. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
Langdahl B
Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Barrionuevo P; Kapoor E; Asi N; Alahdab F; Mohammed K; Benkhadra K; Almasri J; Farah W; Sarigianni M; Muthusamy K; Al Nofal A; Haydour Q; Wang Z; Murad MH
J Clin Endocrinol Metab; 2019 May; 104(5):1623-1630. PubMed ID: 30907957
[TBL] [Abstract][Full Text] [Related]
12. Postmenopausal Osteoporosis: A Clinical Review.
Watts NB
J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
14. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
Reginster JY
Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
[TBL] [Abstract][Full Text] [Related]
15. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
Fleurence RL; Iglesias CP; Johnson JM
Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and Treatment of Osteoporosis.
O'Connor KM
Med Clin North Am; 2016 Jul; 100(4):807-26. PubMed ID: 27235616
[TBL] [Abstract][Full Text] [Related]
17. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
[TBL] [Abstract][Full Text] [Related]
18. An overview of the management of osteoporosis in the aging female population.
Amin U; McPartland A; O'Sullivan M; Silke C
Womens Health (Lond); 2023; 19():17455057231176655. PubMed ID: 37218715
[TBL] [Abstract][Full Text] [Related]
19. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
20. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
